Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ionis Pharmaceuticals, Inc. - Common Stock (NQ:IONS)

42.17 +0.35 (+0.84%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,596,369
Open 41.70
Bid (Size) 41.00 (2)
Ask (Size) 42.97 (2)
Prev. Close 41.82
Today's Range 41.70 - 42.57
52wk Range 23.95 - 50.43
Shares Outstanding 141,797,854
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
What's Going On With Takeda Stock On Friday?
Takeda stock steadies after early dip as FDA clears Ionis' Dawnzera for hereditary angioedema, posing fresh competition to Takeda's Takhzyro. 
Via Benzinga
Beyond The Numbers: 10 Analysts Discuss Ionis Pharmaceuticals Stock
 
Via Benzinga

Performance

YTD
+21.6%
+21.6%
1 Month
+2.4%
+2.4%
3 Month
+26.6%
+26.6%
6 Month
+32.2%
+32.2%
1 Year
-9.9%
-9.9%

More News

Read More
Retail Traders Pile Into Ionis As Wall Street Hikes Price Targets On FDA Approval Of Swelling Disorder Therapy
Via Stocktwits
Ionis Pharma Wins FDA Nod For First RNA-Targeted Therapy For Rare Genetic Swelling Disorder
Via Benzinga
DAWNZERA™ (donidalorsen) approved in the U.S. as first and only RNA-targeted prophylactic treatment for hereditary angioedema
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Earnings Scheduled For July 30, 2025
Via Benzinga
An Overview of Ionis Pharmaceuticals's Earnings
Via Benzinga
IONS Premarket Gains 2.4% After C-Suite Insider Sells $440K In Stock
Via Benzinga
Ionis (IONS) Q2 Revenue Soars 101%
Via The Motley Fool
Deep Dive Into Ionis Pharmaceuticals Stock: Analyst Perspectives (6 Ratings)
Via Benzinga
Ionis (IONS) Q2 2025 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Ionis Posts Surprise Q2 Profit, Double Revenues On Stronger Sales From Newly Approved Genetic Disease Drug
Via Benzinga
Ionis reports second quarter 2025 financial results and highlights progress on key programs
From Ionis Pharmaceuticals, Inc.
Via Business Wire
TRYNGOLZA® (olezarsen) recommended for approval in the EU by CHMP for familial chylomicronemia syndrome (FCS)
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Phase 3 OASISplus data demonstrating benefit of donidalorsen for HAE patients who switched from other prophylactics published in JACI In Practice
From Ionis Pharmaceuticals, Inc.
Via Business Wire
IONIS PHARMACEUTICALS INC (NASDAQ:IONS) - A Strong Technical Setup Worth Watching
Via Chartmill
Ionis to hold second quarter 2025 financial results webcast
From Ionis Pharmaceuticals, Inc.
Via Business Wire
This Nike Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
Via Benzinga
10 Analysts Assess Ionis Pharmaceuticals: What You Need To Know
Via Benzinga
New Data for Nusinersen Underscore Biogen’s Commitment to Advancing Clinical Research to Improve Outcomes in SMA
From Biogen Inc.
Via GlobeNewswire
Biogen-Ionis Partnered Drug Shows Benefit In Children With Spinal Muscular Atrophy Previously Treated With Novartis' Zolgensma
Via Benzinga
Ionis announces Biogen to advance salanersen into SMA registrational studies based on positive interim Phase 1 results
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results
From Biogen Inc.
Via GlobeNewswire
Can Biogen Outdo Its Own Spinal Muscular Atrophy Drug?
Via Investor's Business Daily
Analyst Expectations For Ionis Pharmaceuticals's Future
Via Benzinga

Frequently Asked Questions

Is Ionis Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Ionis Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Ionis Pharmaceuticals, Inc. - Common Stock trade on?
Ionis Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Ionis Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Ionis Pharmaceuticals, Inc. - Common Stock is IONS on the Nasdaq Stock Market
What is the current price of Ionis Pharmaceuticals, Inc. - Common Stock?
The current price of Ionis Pharmaceuticals, Inc. - Common Stock is 42.17
When was Ionis Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Ionis Pharmaceuticals, Inc. - Common Stock was at 08/26/25 04:00 PM ET
What is the market capitalization of Ionis Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Ionis Pharmaceuticals, Inc. - Common Stock is 5.98B
How many shares of Ionis Pharmaceuticals, Inc. - Common Stock are outstanding?
Ionis Pharmaceuticals, Inc. - Common Stock has 6B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.